OptimizeRx Corp. (OPRX) - What Are Researchers Thinking About This Stock?

Key Points

• Analysts have a “Moderate Buy” consensus on OptimizeRx, with six buys, two holds and one sell among nine ratings. The average 12-month price target is $11.57, above the reported share price of $8.29.
• OptimizeRx reported quarterly EPS of $0.16, beating the $0.11 consensus estimate, while revenue of $20.5 million slightly exceeded expectations. Analysts forecast full-year EPS of $0.49.
• Institutional investors own 76.47% of the stock, with several funds initiating or increasing positions. The shares have recently traded above their 50-day and 200-day moving averages but remain well below the 52-week high of $22.25.

Shares of OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $11.57.

Several analysts recently issued reports on OPRX shares. UBS Group set a $11.00 target price on shares of OptimizeRx in a research report on Friday, August 14th. Stifel Nicolaus set a $12.00 target price on shares of OptimizeRx in a report on Thursday, August 13th. Wall Street Zen cut shares of OptimizeRx from a "strong-buy" rating to a "buy" rating in a report on Monday, July 20th. Citigroup reiterated a "market outperform" rating on shares of OptimizeRx in a research report on Friday, August 14th. Finally, Weiss Ratings upgraded shares of OptimizeRx from a "sell (d)" rating to a "sell (d+)" rating in a research note on Tuesday, August 25th.

Institutional Investors Weigh In On OptimizeRx

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Corient Private Wealth LP purchased a new position in OptimizeRx during the second quarter valued at $77,000. AWM Investment Company Inc. bought a new stake in OptimizeRx during the second quarter valued at about $1,375,000. Bank of New York Mellon Corp purchased a new stake in OptimizeRx in the second quarter worth about $370,000. Segall Bryant & Hamill LLC purchased a new stake in OptimizeRx in the first quarter worth about $1,185,000. Finally, Quantinno Capital Management LP increased its position in OptimizeRx by 180.1% in the first quarter. Quantinno Capital Management LP now owns 49,022 shares of the company's stock worth $308,000 after buying an additional 31,518 shares in the last quarter. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

OptimizeRx Trading Down 1.7%

OptimizeRx stock opened at $8.29 on Thursday. The business has a 50-day simple moving average of $7.88 and a two-hundred day simple moving average of $6.62. The company has a market cap of $156.15 million, a P/E ratio of 36.05 and a beta of 1.26. OptimizeRx has a 52-week low of $4.54 and a 52-week high of $22.25. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 0.14.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.11 by $0.05. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. The firm had revenue of $20.50 million during the quarter, compared to analyst estimates of $20.20 million. Analysts predict that OptimizeRx will post 0.49 EPS for the current year.

OptimizeRx Company Profile

OptimizeRx Corporation is a digital health company that provides technology and communication solutions for the life sciences and healthcare industries. Its platform connects pharmaceutical and biotechnology companies with healthcare providers and patients through digital channels integrated into electronic health records, electronic prescribing systems and other clinical workflows.

The company's solutions support activities such as delivering treatment information, patient savings and affordability offers, medication adherence programs, and other communications intended to help patients access and remain on prescribed therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.